Micronics Acquires License to Molecular Beacons Technology

Company is advancing point-of-care molecular diagnostic applications
REDMOND, Wash.--(Business Wire)--
Micronics, Inc., a leading developer of point-of-care molecular and
immunohematology diagnostic products, announced today that it has entered into a
license agreement with PHRI Properties, Inc., a nonprofit corporation wholly
owned by the University of Medicine & Dentistry of New Jersey, for the right to
make, have made, use and sell Micronics` products that incorporate PHRI`s
molecular beacons technology.

Micronics is advancing a family of near-patient, point-of-care molecular tests
for infectious disease diagnosis and forensic testing. These tests employ
Micronics` microfluidics technologies, which enable substantial reductions in
both the volume of a sample taken from a patient and the amount of reagents
required to perform a nucleic acid amplification assay for the detection of the
unique genes present in infectious disease pathogens. Molecular beacons are
highly specific probes that fluoresce in a characteristic color if a target gene
is present in a patient`s sample. These probes are incorporated into Micronics`
microfluidics cartridges for ease of use and prolonged storage at room
temperature. The cartridges can perform either single or multiplex pathogen
detection. Each cartridge is processed by a lightweight, low-cost,
battery-powered instrument with enabled software connectivity. Micronics` tests
are designed to provide a result in under thirty minutes, directly from sample
acquisition in a sealed disposable cartridge.

About Micronics

Micronics is a privately held company located in Redmond, Washington that is
advancing a unique portfolio of point-of-care molecular diagnostic products for
infectious disease detection, diagnosis and treatment monitoring. The Company
has developed a significant patent estate in microfluidics and related
technologies that enable the processing of biological and environmental samples
directly in disposable devices, and the performance of highly accurate and
affordable tests in a fraction of the time required by most molecular diagnostic
tests in use today. The Company also provides custom product development on
behalf of partners and clients worldwide. For additional information, please
visit www.micronics.net.

About PHRI Properties, Inc.

Molecular beacons technology was developed at The Public Health Research
Institute (PHRI), which began as an independent, not-for-profit research
organization, founded in 1941 in New York City. In 2002, PHRI moved to the
International Center for Public Health at the University of Medicine & Dentistry
of New Jersey (UMDNJ), bringing together under one roof PHRI, the Department of
Microbiology and Molecular Genetics of the New Jersey Medical School, and the
Global Tuberculosis Institute. In December 2006, PHRI was officially
incorporated into the New Jersey Medical School, and molecular beacons
technology was assigned to PHRI Properties, Inc. For additional information,
please visit www.molecular-beacons.org.

Micronics
President/CEO
Karen Hedine, 425-895-9197 x 126
khedine@micronics.net

Copyright Business Wire 2009